Sorrento’s Biosimilar Candidates Successful in Phase 3

January 15, 2016

Sorrento Therapeutics’ investigational biosimilars for treating advanced colorectal cancer and rheumatoid arthritis met primary endpoints in pivotal Phase 3 trials, the California drugmaker reported last week.

Studied in China by partner MabTech, STI-001 and STI-002 are copies of Eli Lilly’s Erbitux chemotherapy and Janssen Biotech’s Remicade.

MabTech currently is filing in China for the biosimilars, while Sorrento is responsible for its production in the U.S. and other jurisdictions.